Evaluation of Efficacy/Safety of EVE-PMS Skin Test Panel


EVE Medical Systems

Status and phase

Phase 2


Premenstrual Syndrome


Drug: Skin test panel

Study type


Funder types




Details and patient eligibility


The EVE-PMS technology is intended for determination of intolerance or sensitivity to sex hormones, among women suffering from severe PreMenstrual Syndrome (PMS). The system includes skin testing panel for identification of hormones to which the patients might be sensitive. Tests are applied close to the ovulation period and the skin reaction is examined in 20 minutes, 48 hours and daily during the following month. Results of skin tests and patient's history will determine the value of EVE-PMS Skin-Test Panel as a diagnostic tool for severe PMS patients.


40 estimated patients




20 to 45 years old


Accepts Healthy Volunteers

Inclusion criteria

  1. Person is over the age of 20 but not older than age 45.

  2. Person is willing to participate as evidenced by signing the written informed consent form.

  3. Suffers from known dominant severe symptom of breast swelling and tenderness (level 7-10 according to standard scale of PMS symptoms severity)

  4. Other severe symptoms of Premenstrual syndrome (based on WHO and ACOG criteria). This may include one or more of PMS symptoms with level 7-10 according to standard scale of PMS symptoms severity.

  5. At work, school, home, or in daily routine, at least one of the PMS symptoms caused reduction of productivity or inefficiency

  6. At least one of the PMS symptoms caused avoidance of or less participation in hobbies or social activities

  7. At least one of the PMS symptoms interfere with relationships with others:

    i. Timing of PMS symptom(s): during the 14 days prior to onset of menstrual flow (rather than spotting) and up to 5 days during the menstrual flow.

ii. Pattern and length of PMS symptomatic period: minimum of 2 days, up to 14 days.

iii. For PMS diagnosis two out of last three consecutive menstrual cycles were monitored by daily monitoring of symptoms.

iv. Timing and length of asymptomatic phase: day 6 to at least day 10 of the menstrual cycle.

v. Cyclicity - presentation of the 'off-on' phenomenon: there should be a clear shift from no PMS symptoms to PMS symptoms.

vi. Reliable non hormonal contraception.

Exclusion criteria

  1. Pregnant or lactating woman
  2. Oral contraceptives during last three months, including hormonal IUD (trade name mirena).
  3. Serious health problems.
  4. Unexplained menstrual disorders.
  5. Treated by hormones (estrogen and progesterone).
  6. For healthy: Irregular or abnormal test results.

Trial design

Primary purpose




Interventional model

Factorial Assignment


Single Blind

40 participants in 2 patient groups

Healthy Control group
Experimental group
Drug: Skin test panel
Experimental group
Drug: Skin test panel

Trial contacts and locations



Central trial contact

Yonit Bomstein, Dr.; Alek Itsekson, Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems